IRONWOOD PHARMACEUTICALS INC 8-K/A

What Happened

• Ironwood Pharmaceuticals Inc. filed an 8-K on May 21, 2026 reporting that on May 19, 2026 the Company’s Committee approved Mark Silver’s assignment as interim chief financial officer and principal financial officer.
• In connection with the interim role, the Committee approved a monthly interim assignment fee of $12,250 and granted Mr. Silver 25,000 restricted stock units (RSUs) under the Company’s 2019 Amended and Restated Equity Incentive Plan. The RSUs vest 50% on each of the first two anniversaries of the grant date.

Key Details

• Interim CFO assignment effective May 19, 2026; fee = $12,250 per month.
• Equity grant = 25,000 RSUs convertible into Class A common stock upon vesting.
• RSU vesting schedule = 50% (~12,500 RSUs) vest on each of the first and second anniversaries.
• Interim fee continues until the earlier of the appointment of a permanent CFO or termination of the interim assignment.

Why It Matters

• This filing documents how Ironwood is covering its chief financial responsibilities while searching for or appointing a permanent CFO.
• The monthly fee is a recurring cash compensation item until the interim assignment ends; the RSUs are an equity-based payment that may dilute shares if and when they vest and convert to common stock.
• Investors should note the company’s disclosure of interim executive compensation and the potential near-term impact on operating expenses and share count from these arrangements.